Drug Profile
Etanercept biosimilar - Qilu Pharmacetuical
Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Qilu Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ankylosing spondylitis; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Ankylosing-spondylitis in China (SC, Injection)
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in China (SC, Injection)
- 26 Nov 2015 Clinical trials in Ankylosing spondylitis in China (SC)